{"id":"epidermal-growth-factor","safety":{"commonSideEffects":[{"rate":null,"effect":"Local irritation or erythema at application site"},{"rate":null,"effect":"Allergic reactions"},{"rate":null,"effect":"Infection risk at wound site"}]},"_chembl":null,"_dailymed":{"setId":"7805055c-e5f6-4d1d-9449-a5dce8a066eb","title":"GUNA-STOMACH (ACTIVATED CHARCOAL - ANTIMONY TRISULFIDE - BISMUTH SUBNITRATE - DIOSCOREA VILLOSA ROOT - DOPAMINE - HUMAN EPIDERMAL GROWTH FACTOR - IPECAC - OREGANO - PICEA MARIANA RESIN - ROBINIA PSEUDOACACIA BARK - SEMECARPUS ANACARDIUM JUICE - SILVER NITRATE - SUS SCROFA STOMACH - SUS SCROFA SYMPATHETIC NERVE - MOMORDICA BALSAMINA IMMATURE FRUIT -) PELLET [GUNA SPA]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"EGF is a naturally occurring polypeptide growth factor that stimulates cellular growth and proliferation by binding to EGFR, a receptor tyrosine kinase. This interaction triggers intracellular signaling cascades that promote wound healing, tissue repair, and epithelial cell regeneration. The marketed formulation is typically used topically or systemically to accelerate healing of damaged tissues and wounds.","oneSentence":"Epidermal growth factor (EGF) binds to and activates the epidermal growth factor receptor (EGFR) on cell surfaces, promoting cell proliferation, differentiation, and survival.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:21:59.928Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Wound healing and tissue repair"},{"name":"Burn injuries"},{"name":"Chronic wounds"},{"name":"Corneal ulcers and ocular surface disease"}]},"trialDetails":[{"nctId":"NCT07498595","phase":"EARLY_PHASE1","title":"TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-03-31","conditions":"EGFR-TKI-resistant Non-Small Cell Lung Cancer","enrollment":50},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT06635447","phase":"PHASE3","title":"Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-26","conditions":"Breast Cancer","enrollment":258},{"nctId":"NCT06305754","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":520},{"nctId":"NCT07137416","phase":"PHASE1","title":"Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-05","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma","enrollment":36},{"nctId":"NCT07154290","phase":"PHASE2","title":"A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-18","conditions":"Advanced/Metastatic Non-Small Cell Lung Cancer","enrollment":300},{"nctId":"NCT07498413","phase":"","title":"Epidemiology and Treatment of HR+/HER2- Breast Cancer in England","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-06-08","conditions":"Breast Cancer","enrollment":218677},{"nctId":"NCT02503722","phase":"PHASE1","title":"Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-23","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7","enrollment":36},{"nctId":"NCT02496663","phase":"PHASE1","title":"Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-11","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":138},{"nctId":"NCT07043725","phase":"PHASE3","title":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-09-15","conditions":"HER2-positive Breast Cancer","enrollment":544},{"nctId":"NCT06058377","phase":"PHASE3","title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-11-27","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma","enrollment":3680},{"nctId":"NCT07498478","phase":"PHASE2","title":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment","status":"RECRUITING","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2026-03-17","conditions":"Breast Cancer","enrollment":94},{"nctId":"NCT06418724","phase":"PHASE2","title":"Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2026-07-30","conditions":"Locally Advanced Cutaneous Squamous Cell Carcinoma","enrollment":27},{"nctId":"NCT02193282","phase":"PHASE3","title":"Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-02-11","conditions":"Lung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7","enrollment":390},{"nctId":"NCT07326566","phase":"PHASE2","title":"Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII","status":"RECRUITING","sponsor":"Black Diamond Therapeutics, Inc.","startDate":"2026-04","conditions":"Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM","enrollment":162},{"nctId":"NCT04677595","phase":"PHASE2","title":"Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-05-17","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":36},{"nctId":"NCT07287098","phase":"PHASE2","title":"A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-05","conditions":"Breast Neoplasms","enrollment":600},{"nctId":"NCT07493291","phase":"","title":"Effectiveness and Safety of Palbociclib: Brand vs. Generic in Iraqi Stage IV Hormone Receptor-positive / Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer Patients: A Comparative Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Al-Mustansiriyah University","startDate":"2025-09-07","conditions":"Brest Cancer","enrollment":100},{"nctId":"NCT07462377","phase":"PHASE1","title":"A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC","status":"RECRUITING","sponsor":"EpiBiologics","startDate":"2026-04","conditions":"Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation","enrollment":110},{"nctId":"NCT07185997","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations","status":"RECRUITING","sponsor":"ArriVent BioPharma, Inc.","startDate":"2025-12-17","conditions":"Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer","enrollment":480},{"nctId":"NCT06667076","phase":"PHASE2","title":"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":480},{"nctId":"NCT05963997","phase":"PHASE1, PHASE2","title":"A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer","status":"COMPLETED","sponsor":"Carrick Therapeutics Limited","startDate":"2023-10-09","conditions":"Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer","enrollment":49},{"nctId":"NCT06827236","phase":"PHASE1, PHASE2","title":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-04-23","conditions":"Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer","enrollment":380},{"nctId":"NCT04085887","phase":"PHASE1, PHASE2","title":"Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures","status":"RECRUITING","sponsor":"Stanford University","startDate":"2026-04","conditions":"Brain Tumor","enrollment":12},{"nctId":"NCT06188559","phase":"PHASE2","title":"A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2024-04-10","conditions":"Breast Cancer","enrollment":135},{"nctId":"NCT07340541","phase":"PHASE2","title":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-02","conditions":"Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer","enrollment":700},{"nctId":"NCT07485452","phase":"PHASE2","title":"Boosting Osimertinib Blood Brain Barrier Penetration","status":"NOT_YET_RECRUITING","sponsor":"Maastricht University Medical Center","startDate":"2026-04","conditions":"Non-Small Cell Lung Cancer","enrollment":7},{"nctId":"NCT05748834","phase":"PHASE2","title":"Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2023-07-24","conditions":"Breast Cancer","enrollment":36},{"nctId":"NCT05801029","phase":"PHASE2","title":"A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-07-18","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":60},{"nctId":"NCT07100080","phase":"PHASE2, PHASE3","title":"Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-11-05","conditions":"Non-Small Cell Lung Cancer","enrollment":596},{"nctId":"NCT07483034","phase":"NA","title":"Receptive Music Therapy Effects on Anxiety, Depression, QoL, and EGF, IL-8, and NfL During the Breast Cancer Treatment.","status":"ENROLLING_BY_INVITATION","sponsor":"Brigita Vilc","startDate":"2024-10-01","conditions":"Breast Cancer Invasive, Chemotherapy, Breast Cancer Surgery","enrollment":90},{"nctId":"NCT04538664","phase":"PHASE3","title":"A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-10-13","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":308},{"nctId":"NCT05659563","phase":"PHASE2","title":"Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%","status":"COMPLETED","sponsor":"MedSIR","startDate":"2023-07-20","conditions":"Breast Cancer, Breast Cancer, Early-Onset","enrollment":92},{"nctId":"NCT05379595","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-29","conditions":"Advanced or Metastatic Colorectal Cancer","enrollment":225},{"nctId":"NCT06671379","phase":"PHASE3","title":"A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-11-29","conditions":"Non-small Cell Lung Cancer","enrollment":498},{"nctId":"NCT06590857","phase":"PHASE1, PHASE2","title":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.","status":"ACTIVE_NOT_RECRUITING","sponsor":"RayzeBio, Inc.","startDate":"2024-07-19","conditions":"Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer","enrollment":16},{"nctId":"NCT05323955","phase":"PHASE2","title":"Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Carey Anders, M.D.","startDate":"2023-03-23","conditions":"Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer","enrollment":48},{"nctId":"NCT06934889","phase":"PHASE1","title":"Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-04-07","conditions":"Glioblastoma, Gliosarcoma","enrollment":60},{"nctId":"NCT04298606","phase":"EARLY_PHASE1","title":"A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2021-11-22","conditions":"Chronic Obstructive Pulmonary Disease, Lung Non-Small Cell Carcinoma, Pneumonia","enrollment":20},{"nctId":"NCT06618287","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-02-04","conditions":"Lung Cancer, Breast Cancer","enrollment":416},{"nctId":"NCT05388669","phase":"PHASE3","title":"A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-08-05","conditions":"Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":418},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Breast Neoplasms, Breast Cancer","enrollment":372},{"nctId":"NCT06256328","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2024-01-10","conditions":"Gastric Cancer","enrollment":226},{"nctId":"NCT06843967","phase":"PHASE1, PHASE2","title":"A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-02-19","conditions":"Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma, Liposarcoma","enrollment":54},{"nctId":"NCT06120140","phase":"PHASE2","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":300},{"nctId":"NCT06038539","phase":"PHASE3","title":"Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer","status":"TERMINATED","sponsor":"Biocon Biologics UK Ltd","startDate":"2025-01-06","conditions":"HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients","enrollment":55},{"nctId":"NCT05364073","phase":"PHASE1","title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"ArriVent BioPharma, Inc.","startDate":"2022-06-30","conditions":"Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer","enrollment":160},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT07100106","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2025-10-07","conditions":"Breast Cancer","enrollment":285},{"nctId":"NCT04862663","phase":"PHASE3","title":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-05-10","conditions":"Locally Advanced (Inoperable) or Metastatic Breast Cancer","enrollment":895},{"nctId":"NCT05913440","phase":"","title":"HER2-low Unresectable and/or Metastatic Breast Cancer in Russia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-05-30","conditions":"Breast Cancer","enrollment":1669},{"nctId":"NCT05099172","phase":"PHASE1, PHASE2","title":"First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2021-10-25","conditions":"Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation","enrollment":370},{"nctId":"NCT07070232","phase":"PHASE1, PHASE2","title":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-08-12","conditions":"Advanced Solid Tumor","enrollment":980},{"nctId":"NCT06902545","phase":"","title":"A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.","status":"RECRUITING","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2025-04-03","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":377},{"nctId":"NCT06011772","phase":"EARLY_PHASE1","title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-12-18","conditions":"Colo-rectal Cancer","enrollment":2},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT04895358","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-18","conditions":"Breast Neoplasms","enrollment":340},{"nctId":"NCT03381274","phase":"PHASE1, PHASE2","title":"Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2018-05-08","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":43},{"nctId":"NCT07310420","phase":"PHASE1","title":"A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"TerSera Therapeutics LLC","startDate":"2026-04-29","conditions":"Advanced Breast Cancer","enrollment":88},{"nctId":"NCT04572295","phase":"PHASE1","title":"A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Co., Ltd.","startDate":"2020-10-09","conditions":"Breast Neoplasms","enrollment":51},{"nctId":"NCT05973773","phase":"PHASE3","title":"REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-12-18","conditions":"Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation","enrollment":285},{"nctId":"NCT05967689","phase":"PHASE2","title":"A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.","status":"RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-07-31","conditions":"Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations","enrollment":220},{"nctId":"NCT03330847","phase":"PHASE2","title":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-03-07","conditions":"Metastatic Triple Negative Breast Cancer","enrollment":273},{"nctId":"NCT07413939","phase":"PHASE2, PHASE3","title":"RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive","status":"NOT_YET_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-04-30","conditions":"HER2-positive Breast Cancer","enrollment":650},{"nctId":"NCT07063693","phase":"PHASE1","title":"ABY-029 Glioma Trial","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2026-02-17","conditions":"Intracranial Tumor","enrollment":33},{"nctId":"NCT04285671","phase":"PHASE1, PHASE2","title":"Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2021-01-29","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8","enrollment":30},{"nctId":"NCT05636267","phase":"PHASE1, PHASE2","title":"Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients","status":"TERMINATED","sponsor":"Akeso","startDate":"2023-02-10","conditions":"NSCLC","enrollment":59},{"nctId":"NCT07020221","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","status":"RECRUITING","sponsor":"Verastem, Inc.","startDate":"2025-06-24","conditions":"Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer","enrollment":295},{"nctId":"NCT04589845","phase":"PHASE2","title":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-01-18","conditions":"Solid Tumors","enrollment":920},{"nctId":"NCT06194448","phase":"PHASE2","title":"To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-21","conditions":"Lung Cancer","enrollment":76},{"nctId":"NCT03260491","phase":"PHASE1","title":"U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2017-10-30","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":312},{"nctId":"NCT06018337","phase":"PHASE3","title":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"DualityBio Inc.","startDate":"2024-01-18","conditions":"Metastatic Breast Cancer","enrollment":541},{"nctId":"NCT05526755","phase":"PHASE2","title":"A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-03-06","conditions":"Stage II-IIIB Non-small Cell Lung Carcinoma","enrollment":188},{"nctId":"NCT07214662","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2026-01-13","conditions":"Breast Cancer","enrollment":136},{"nctId":"NCT06760819","phase":"PHASE2","title":"A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","status":"RECRUITING","sponsor":"Bayer","startDate":"2025-02-13","conditions":"Advanced Solid Tumors, HER2 Mutation","enrollment":111},{"nctId":"NCT07367516","phase":"PHASE1, PHASE2","title":"Clinical Trial Evaluating TQB6411 Injection in Subjects With Esophageal Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2026-02-12","conditions":"Esophageal Cancer","enrollment":105},{"nctId":"NCT05184712","phase":"PHASE3","title":"Phase 3 Clinical Study of AK112 for NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-01-25","conditions":"Non-Squamous Non-small Cell Lung Cancer","enrollment":322},{"nctId":"NCT03701334","phase":"PHASE3","title":"A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-07","conditions":"Early Breast Cancer","enrollment":5101},{"nctId":"NCT05579366","phase":"PHASE1, PHASE2","title":"Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)","status":"RECRUITING","sponsor":"Genmab","startDate":"2022-12-07","conditions":"High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma","enrollment":764},{"nctId":"NCT06147037","phase":"PHASE1","title":"A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-07-31","conditions":"Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma","enrollment":70},{"nctId":"NCT06982521","phase":"PHASE3","title":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Relay Therapeutics, Inc.","startDate":"2025-08-26","conditions":"PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor","enrollment":540},{"nctId":"NCT05827081","phase":"PHASE3","title":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-28","conditions":"Early Breast Cancer","enrollment":1400},{"nctId":"NCT06417814","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-10-04","conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":744},{"nctId":"NCT06452277","phase":"PHASE3","title":"A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-08-28","conditions":"Advanced Non-small Cell Lung Cancer, HER2 Mutation","enrollment":278},{"nctId":"NCT06760637","phase":"PHASE3","title":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-01-06","conditions":"Breast Cancer","enrollment":1020},{"nctId":"NCT05325632","phase":"PHASE2","title":"Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-10-28","conditions":"HER2-positive Breast Cancer","enrollment":53},{"nctId":"NCT05573893","phase":"","title":"PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-09-12","conditions":"Breast Neoplasms, Breast Cancer, Neoplasm Metastasis","enrollment":800},{"nctId":"NCT07049055","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer","status":"RECRUITING","sponsor":"Engeneic Pty Limited","startDate":"2026-01-12","conditions":"Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":144},{"nctId":"NCT04498481","phase":"","title":"TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-03-01","conditions":"Breast Cancer","enrollment":1},{"nctId":"NCT04288089","phase":"PHASE1","title":"A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2020-04-01","conditions":"Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms","enrollment":31},{"nctId":"NCT06239220","phase":"PHASE2","title":"PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC","status":"RECRUITING","sponsor":"Glenn J. Hanna","startDate":"2024-02-16","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer","enrollment":25},{"nctId":"NCT05187832","phase":"PHASE1","title":"A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Kind Pharmaceuticals LLC","startDate":"2022-10-05","conditions":"Advanced or Metastatic Breast Cancer","enrollment":61},{"nctId":"NCT00003809","phase":"PHASE3","title":"Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-08-06","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT05593094","phase":"PHASE1, PHASE2","title":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-09-03","conditions":"Advanced Solid Tumors, HER2-positive Breast Cancer","enrollment":210},{"nctId":"NCT04886726","phase":"PHASE1","title":"PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis","status":"RECRUITING","sponsor":"Henry Ford Health System","startDate":"2021-12-23","conditions":"Graft Versus Host Disease","enrollment":18},{"nctId":"NCT07431281","phase":"PHASE3","title":"Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-03","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer","enrollment":2130},{"nctId":"NCT05113251","phase":"PHASE3","title":"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-25","conditions":"Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer","enrollment":927},{"nctId":"NCT07181681","phase":"PHASE1","title":"A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-11-10","conditions":"Solid Tumors, Advanced Solid Tumor","enrollment":63},{"nctId":"NCT07427394","phase":"PHASE2","title":"Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-04-10","conditions":"Advanced Breast Cancer","enrollment":24},{"nctId":"NCT06761976","phase":"","title":"Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation","status":"AVAILABLE","sponsor":"Bayer","startDate":"","conditions":"Advanced Non-small Cell Lung Cancer, Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":92910,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Epidermal Growth Factor Serum"],"phase":"marketed","status":"active","brandName":"epidermal growth factor","genericName":"epidermal growth factor","companyName":"Chinese PLA General Hospital","companyId":"chinese-pla-general-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"Epidermal growth factor (EGF) binds to and activates the epidermal growth factor receptor (EGFR) on cell surfaces, promoting cell proliferation, differentiation, and survival. Used for Wound healing and tissue repair, Burn injuries, Chronic wounds.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}